Botulinum Toxin Type A Injection [HG102] — Competitive Intelligence Brief

Botulinum Toxin Type A Injection [HG102] (Botulinum Toxin Type A Injection [HG102]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; botulinum toxin preparation. Area: Neurology; Aesthetics; Pain Management.

phase 3 Neurotoxin; botulinum toxin preparation SNARE proteins (synaptobrevin/VAMP); acetylcholine release machinery Neurology; Aesthetics; Pain Management Small molecule

Target snapshot

Botulinum Toxin Type A Injection [HG102] (Botulinum Toxin Type A Injection [HG102]) — Hugel. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Botulinum Toxin Type A Injection [HG102] TARGET	Botulinum Toxin Type A Injection [HG102]	Hugel	phase 3	Neurotoxin; botulinum toxin preparation	SNARE proteins (synaptobrevin/VAMP); acetylcholine release machinery
Botulinum Toxin A (Botox )	Botulinum Toxin A (Botox )	Assistance Publique - Hôpitaux de Paris	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25); acetylcholine release machinery
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)
Botulinum Toxin Type-A (day 0)	Botulinum Toxin Type-A (day 0)	Ivo Pitanguy Institute	marketed	Neurotoxin; neuromuscular blocking agent	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kDa	Botulinum Toxin Type A 900kDa	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
Botulinum Toxin Type A 900kD	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; botulinum toxin preparation class)

1. Hugel · 2 drugs in this class